Heart stem cell therapy after a major heart attack holds the promise of helping to repair severely damaged cells by encouraging the growth of new ones. However, the process which involves infusing healthy stem cells into the heart to replace the damaged tissue has had limited success in clinical trials. In order to get the most benefit from heart stem cell treatment, it is essential for doctors to properly place the cells in the heart. But, once the stem cells are injected, its difficult to determine exactly where they wind up, and many scientists believe faulty placement is ultimately the culprit of the therapys disappointing results. Now, that problem could be potentially solved with a new visualization technique developed by Dr. Sam Gambhir and fellow researchers at Stanford University School of Medicine in California. Their study, published in Science Translational Medicine, details the invention of silica nanoparticles, which can be injected inside stem cells, acting as tiny tracking devices that allow doctors to see the stem cells path inside the body. According to the studys researchers, the most encouraging results from heart stem cell therapy have been seen after bypass surgery, which is done right after a patient has suffered … Continue reading →

CARLSBAD, CA--(Marketwire - Mar 20, 2013) - International Stem Cell Corporation (ISCC) ( OTCQB : ISCO ) (www.internationalstemcell.com), a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells today announced positive results demonstrating the safety and efficacy of stem cell engraftment in a primate model of Parkinson's disease. The results were presented during the American Academy of Neurology (AAN) 65th Annual Meeting, Scientific Platform Session: Parkinson's Disease Therapeutics on Wednesday, March 20, 2013 in San Diego. "This pilot study represents a first essential step in bringing cell-based therapies for Parkinson's disease to clinical trials," commented co-author of the study Evan Y. Snyder, MD, PhD, Director of Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute. These placebo-controlled studies were designed to demonstrate the viability, fate and functional efficacy of the stem cell derived neural cells after implantation to the brain. Highly pure populations of neuronal cells were differentiated from human parthenogenetic stem cells (hpSC) according to the protocol developed by International Stem Cell Corporation and recently published in the Nature Publishing Group's Scientific Reports. The studies employ MPTP-lesioned African Green monkeys and 6-OHDA-lesioned rats, the principle models used to study Parkinson's disease. The … Continue reading →

Nanomedicine drug delivery in cancer - Mark E. Davis - Na Newest concept of drug dilevery system (nano prticles of drugs) for treatment of cancer. By: kulachi2011 … Continue reading →

MagForce AG / MagForce successfully implements capital increase . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * MagForce successfully completes capital increase in the total amount of EUR33.5 million * New funding secures financing of post-marketing trial of the NanoTherm therapy in glioblastoma and FDA filing * Next cancer indication in clinical development will be prostate cancer Berlin, Germany, March 20, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, today anounced that it has successfully completed a capital increase against cash and non-cash contributions including preemptive rights in the total amount of EUR33.5 million. In total, 18,606,553 new no-par value bearer shares have been subscribed. Thereof 9,750,846 new shares have been subscribed against cash and 8,855,707 new shares have been subscribed against a contribution in kind, namely converting EUR15.9 million shareholder loans into equity. As a result, MagForce is debt-free and has EUR17.6 million cash on hand to drive the company through the next inflection points. Prof. Hoda Tawfik, COO and co-CEO of MagForce AG, commented: "With this capital increase, Magforce is entering a new phase. … Continue reading →

MagForce successfully completes capital increase in the total amount of 33.5 million New funding secures financing of post-marketing trial of the NanoTherm therapy in glioblastoma and FDA filing Next cancer indication in clinical development will be prostate cancer Berlin, Germany, March 20, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, today anounced that it has successfully completed a capital increase against cash and non-cash contributions including preemptive rights in the total amount of 33.5 million. In total, 18,606,553 new no-par value bearer shares have been subscribed. Thereof 9,750,846 new shares have been subscribed against cash and 8,855,707 new shares have been subscribed against a contribution in kind, namely converting 15.9 million shareholder loans into equity. As a result, MagForce is debt-free and has 17.6 million cash on hand to drive the company through the next inflection points. Prof. Hoda Tawfik, COO and co-CEO of MagForce AG, commented: "With this capital increase, Magforce is entering a new phase. With the successful capital increase we have set the preconditions for establishing the NanoTherm Therapy in the medical community and for achieving the validation of the clinical data in Europe … Continue reading →

Heart stem cell therapy after a major heart attack holds the promise of helping to repair severely damaged cells by encouraging the growth of new ones. However, the process which involves infusing healthy stem cells into the heart to replace the damaged tissue has had limited success in clinical trials. In order to get the most benefit from heart stem cell treatment, it is essential for doctors to properly place the cells in the heart. But, once the stem cells are injected, its difficult to determine exactly where they wind up, and many scientists believe faulty placement is ultimately the culprit of the therapys disappointing results. Now, that problem could be potentially solved with a new visualization technique developed by Dr. Sam Gambhir and fellow researchers at Stanford University School of Medicine in California. Their study, published in Science Translational Medicine, details the invention of silica nanoparticles, which can be injected inside stem cells, acting as tiny tracking devices that allow doctors to see the stem cells path inside the body. According to the studys researchers, the most encouraging results from heart stem cell therapy have been seen after bypass surgery, which is done right after a patient has suffered … Continue reading →

SOURCE: International Stem Cell Corporation CARLSBAD, CA--(Marketwire - Mar 19, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today safety and encouraging efficacy of stem cell therapy in rodent and non-human primate models of Parkinson's disease. "This pilot study represents a first essential step in bringing cell-based therapies for Parkinson's disease to clinical trials," commented co-author of the study Evan Y. Snyder, MD, PhD, Director of Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute. These placebo-controlled studies were designed to demonstrate the viability, fate and functional efficacy of the stem cell derived neural cells after implantation to the brain.Highly pure populations of neuronal cells were differentiated from human parthenogenetic stem cells (hpSC) according to the protocol developed by International Stem Cell Corporation and recently published in the Nature Publishing Group's Scientific Reports. The studies employ MPTP-lesioned African Green monkeys and 6-OHDA-lesioned rats, the principle models used to study Parkinson's disease.The duration of the primate study was four months and the rodent study six months.In the non-human primate model, behavioral endpoints were assessed with parkinsonian scores. These scores, based on a … Continue reading →

CARLSBAD, CA--(Marketwire - Mar 20, 2013) - International Stem Cell Corporation (ISCC) ( OTCQB : ISCO ) (www.internationalstemcell.com), a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells today announced positive results demonstrating the safety and efficacy of stem cell engraftment in a primate model of Parkinson's disease. The results were presented during the American Academy of Neurology (AAN) 65th Annual Meeting, Scientific Platform Session: Parkinson's Disease Therapeutics on Wednesday, March 20, 2013 in San Diego. "This pilot study represents a first essential step in bringing cell-based therapies for Parkinson's disease to clinical trials," commented co-author of the study Evan Y. Snyder, MD, PhD, Director of Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute. These placebo-controlled studies were designed to demonstrate the viability, fate and functional efficacy of the stem cell derived neural cells after implantation to the brain. Highly pure populations of neuronal cells were differentiated from human parthenogenetic stem cells (hpSC) according to the protocol developed by International Stem Cell Corporation and recently published in the Nature Publishing Group's Scientific Reports. The studies employ MPTP-lesioned African Green monkeys and 6-OHDA-lesioned rats, the principle models used to study Parkinson's disease. The … Continue reading →